C4 Therapeutics Inc
NASDAQ:CCCC
EV/S
Enterprise Value to Sales
Enterprise Value to Sales (EV/S) ratio is a valuation multiple that compares the enterprise value (EV) of a company to its revenues. The EV/S multiple gives investors a quantifiable metric of how to value a company based on its sales while taking account of both the company's equity and debt.
Market Cap | EV/S | ||||
---|---|---|---|---|---|
US |
C4 Therapeutics Inc
NASDAQ:CCCC
|
457.9m USD | 9.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
159.7B USD | 7.5 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.4B USD | 6.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 9.3 | ||
AU |
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.9 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 5.5 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.9 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18.4 |
EV/S Forward Multiples
Forward EV/S multiple is a version of the EV/S ratio that uses forecasted revenue for the EV/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.